New York, NY, United States

Time filter

Source Type

News Article | February 28, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, today announced partnerships with two leading fertility organizations: The Donor Solution, an independent egg donation agency, and 3 Sisters Surrogacy, a gestational carrier service. Through these partnerships, more prospective parents will have access to GenePeeks’ proprietary preconception genetic screening test, which assesses combined parental risk of passing on more than 1,000 serious genetic diseases. GenePeeks’ comprehensive approach, called Virtual Progeny Analytics (VPA), uniquely integrates simulated DNA information from two genetic participants to predict the future genome of a child prior to conception. For every mutation in these hypothetical genomes, the company computes a proprietary Variant Gene Dysfunction (VGD) score that predicts gene function and associated disease risk. This next generation approach allows GenePeeks to cover an expanded number of diseases with increased sensitivity and evaluate variants that may remain uncharacterized by other genetic tests, while avoiding the confusion and anxiety that can be associated with carrier testing. In contrast to carrier screening, which identifies parental carrier status, GenePeeks focuses on a future child’s true risk of disease inheritance. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. Over the last ten years, The Donor Solution has helped over 1,000 families to have children, with a success rate of over 82% for first time donors. 3 Sisters Surrogacy provides exceptional support for the increasing number of individuals seeking a gestational carrier to build their family. Clients using the services of either agency will be able to use the GenePeeks test to make more informed reproductive decisions with increased confidence. In addition, The Donor Solution’s donors who have completed the pre-test protocols will be identified as “GenePeeks Ready,” saving prospective parents precious time in their fertility journey. “We are thrilled to partner with The Donor Solution and 3 Sisters Surrogacy, two organizations that share our unrelenting commitment to provide outstanding support on the complicated path of starting a family,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “In addition to reaching more families, these collaborations will allow us to expand our physician network and increase patient access to our next generation technology.” Mary Fusillo, Founder and Executive Director of The Donor Solution and Chief Executive Officer of 3 Sisters Surrogacy, stated, “At The Donor Solution and 3 Sisters Surrogacy, we are committed to providing our clients with the highest quality care possible. Our partnership with GenePeeks is an important step in ensuring that our intended families can protect the future health of their children with access to the most advanced preconception risk screening available.” About GenePeeks GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. GenePeeks’ patented technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s proprietary platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with alternative screening tools. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com. GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact support@genepeeks.com. About The Donor Solution The Donor Solution is a leading egg donor agency in the southwest United States. Known for providing exceptional egg donors, the agency recruits outstanding young women for their program. Founded in 2007 by Mary M. Fusillo, RN, BSN, MS, the agency has helped over 1,000 couples reach their goal of becoming parents. With over 25 years of nursing and hospital management experience, Mary and her team are committed to reducing the stress of the fertility journey while delivering the highest standard of care to both donors and recipients. The organization has offices in Houston and Dallas, Texas and Phoenix, Arizona, with satellite offices in Austin, Texas and Los Angeles/Beverly Hills, California. For more information, visit thedonorsolution.com. About 3 Sisters Surrogacy 3 Sisters Surrogacy is a gestational carrier program dedicated to providing intended parents with the highest level of competence and professionalism. Chief Executive Officer Mary M. Fusillo, RN, BSN, MS has over 16 years of third party parenting experience and donor recruitment, and Chief Scientific Officer Sunday Crider, Ph.D., has worked for 13 years as an IVF embryologist and laboratory director. This combined experience is unique in the industry and has allowed the organization to provide the highest standard of service to all clients. Corporate offices are located in Houston, Texas, with satellite offices in Dallas, Texas and Phoenix, Arizona. For more information, visit 3sisterssurrogacy.com.


News Article | February 15, 2017
Site: www.prweb.com

Executive search firm, Slone Partners, announces the placement of Matt Posard, as President and Chief Commercial Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics executive with extensive commercialization experience. GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. In his new role, Matt will be responsible for leading the commercialization of its products and services as the company enters its next important growth phase. “We are grateful to the talented team at Slone Partners for successfully helping us fill this critical role,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “Matt has an outstanding track record of commercializing novel technologies, which is instrumental to our growth and success of our mission to help reduce a child’s risk of inheriting a genetic disease.” Prior to joining GenePeeks, Mr. Posard has held several leadership roles with innovative organizations including Illumina, Alere and Trovagene. He received a Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego. Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life science tools, clinical trials, contract research, healthcare information technology and laboratory testing industries with offices in Boston, Washington, D.C. and San Francisco.


Methods and systems for assessing the probabilities of the expression of one or more traits in progeny are described.


A device, system and method for predicting gene-dysfunction caused by a genetic mutation in the genome of an organism. A neural network may comprise multiple nodes respectively associated with multiple different gene-dysfunction metrics and multiple different confidence weights. The neural network may combine the multiple gene-dysfunction metrics according to the respective associated confidence weights to generate one or more likelihoods that a genetic mutation causes gene-dysfunction in organisms. In a training-phase, the neural network may be trained using an input data set including genetic mutations to generate new gene-dysfunction metrics and new associated confidence weights that optimize the neural network based on a cost factor. In a run-time phase, a genetic mutation may be identified and one or more likelihoods may be computed that the identified genetic mutation causes gene-dysfunction in the organism based on the new gene-dysfunction metrics and the associated new confidence weights of the neural network.


A system, device and method for receiving multiple aligned genetic sequences obtained from genetic samples of multiple organisms of one or more different species. A measure of evolutionary variation may be computed for one or more alleles at each of one or more aligned genetic loci. The aligned genetic loci in the multiple organisms may be derived from one or more common ancestral genetic loci or may be otherwise related. The measure of evolutionary variation may be a function of variation in alleles at corresponding aligned genetic loci in the multiple aligned genetic sequences. One or more likelihoods may be computed that an allele mutation at each of the one or more genetic loci in a simulated virtual progeny will be deleterious based on the measure of evolutionary variation of alleles at the corresponding aligned genetic loci for the multiple organisms.


A system, device and method for receiving multiple aligned genetic sequences obtained from genetic samples of multiple organisms of one or more different species. A measure of evolutionary variation may be computed for one or more alleles at each of one or more aligned genetic loci. The aligned genetic loci in the multiple organisms may be derived from one or more common ancestral genetic loci or may be otherwise related. The measure of evolutionary variation may be a function of variation in alleles at corresponding aligned genetic loci in the multiple aligned genetic sequences. One or more likelihoods may be computed that an allele mutation at each of the one or more genetic loci in a simulated virtual progeny will be deleterious based on the measure of evolutionary variation of alleles at the corresponding aligned genetic loci for the multiple organisms.


Methods and systems for assessing the probabilities of the expression of one or more traits in progeny are described.


In accordance with an embodiment of the invention, a system and method is provided for determining a probability of a progeny having one or more phenotypes Ph_(j )each associated with a single gene Q_(j). A score sip may be assigned to each allele hip at a plurality of genetic loci (i) in a haploid genome profile H^(p )of a parent (p). A plurality (Nj) of the alleles hkp (k=1, . . . , Nj) associated with the gene Q_(j )may be identified. The scores sip may be mapped or indexed to gene-specific scores j,kp associated with gene Q_(j )for the plurality of (Nj) alleles hkp. A probability may be computed for altering the gene product from gene Q_(j )in a progeny of the parent (p) to be a function of the gene-specific scores j,kp.


News Article | April 18, 2014
Site: gizmodo.com

Remember those slightly horrifying sites that mash up two faces to tell you what your hypothetical babies might look like? With genome sequencing and "virtual embryos," we might actually be able to do that—using science. Those days are not quite here yet, but New Scientist has an intriguing report about a company called GenePeeks. We already screen for common genetic disorders by testing the DNA of prospective parents. GenePeeks goes one step further: its software takes the genome sequences of both parents to produce "10,000 simulated pairings"—in other words, 10,000 virtual, hypothetical children. The company's current test only looks for disease risk, but, as New Scientist points out, its patent is much, much broader. Its technique could screen for any number of traits with a genetic basis, according to the patent, including skin color, breast size, hair texture, and even eyelash length. There are plenty of caveats to pick at, of course, like how siblings from the same family can look quite distinct or how the same kid raised in two different environments turns out differently. But a world in which we can approximate hypothetical children is closer than you might think. Faces reconstructed from the DNA evidence left at, say, crimes scenes are already surprisingly accurate. In the future, you might very well be able to take anyone off the street and imagine what your progeny would look like. Or flick through profiles in a dating app while evaluating potential children—our genetic futures played out in virtual reality. [New Scientist]


Pacific NW Fertility announced today that their center will be the first in the United States to introduce a new technology provided by GenePeeks, a genetic information company. GenePeeks’ new technology, featured last October and July 5, 2015 on CBS’ 60 Minutes, offers parents an innovative option for genetic testing to reduce the risk of hundreds of heritable conditions in their children. GenePeeks’ service at Pacific NW Fertility analyzes a patient’s DNA, in combination with the DNA of prospective egg donors, screening each client/donor combination for hundreds of inherited genetic disorders and diseases. The process uncovers disease risk hidden inside DNA before conception. A personalized catalogue of donors, specifically screened for the patient’s unique genetic profile, assists patients in egg donor selection. GenePeeks also provides patients seeking donor sperm a catalogue of risk-screened donor matches. “This option for parents is unprecedented and we are very excited to be one of the first clinics to offer this to our patients,” Dr. Lorna Marshall of PNWF, says. “All parents want to minimize the chance of their baby having a recessive genetic disorder and this technology maximizes the help we can provide them.” PNWF, home to one of the country’s most successful donor egg programs, is a national leader utilizing frozen donor eggs. Their patients have had over 200 live births using frozen eggs. Utilizing GenePeeks new tools, PNWF’s donors are all genetically screened before being matched with patients. “We’ve tested our egg donors for recessive genetic diseases for many years but GenePeeks takes testing to a whole new level,” Stephanie Frickleton, the donor egg program director at PNWF, says. “Now we can use GenePeeks' technology to help our patients make the best choice, the healthiest choice possible when they select an egg donor.”

Loading GenePeeks collaborators
Loading GenePeeks collaborators